Equities Analysts Offer Predictions for Alkermes Q1 Earnings

Alkermes plc (NASDAQ:ALKS) – Analysts at HC Wainwright lowered their Q1 2025 earnings estimates for shares of Alkermes in a note issued to investors on Thursday, February 13th. HC Wainwright analyst D. Tsao now anticipates that the company will post earnings per share of $0.22 for the quarter, down from their previous forecast of $0.27. HC Wainwright currently has a “Neutral” rating and a $46.00 target price on the stock. The consensus estimate for Alkermes’ current full-year earnings is $2.23 per share. HC Wainwright also issued estimates for Alkermes’ Q2 2025 earnings at $0.31 EPS and Q4 2025 earnings at $0.39 EPS.

Alkermes (NASDAQ:ALKS) last issued its quarterly earnings results on Wednesday, February 12th. The company reported $0.92 earnings per share for the quarter, topping the consensus estimate of $0.81 by $0.11. Alkermes had a net margin of 22.15% and a return on equity of 24.92%.

ALKS has been the subject of several other research reports. JPMorgan Chase & Co. cut their price objective on Alkermes from $32.00 to $26.00 and set a “neutral” rating for the company in a report on Friday, October 25th. Deutsche Bank Aktiengesellschaft began coverage on Alkermes in a report on Tuesday, February 11th. They issued a “buy” rating and a $40.00 price objective for the company. The Goldman Sachs Group increased their price objective on Alkermes from $30.00 to $32.00 and gave the company a “buy” rating in a report on Friday. Cantor Fitzgerald cut their price objective on Alkermes from $48.00 to $43.00 and set an “overweight” rating for the company in a report on Friday, October 25th. Finally, StockNews.com raised Alkermes from a “buy” rating to a “strong-buy” rating in a report on Thursday. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $37.25.

Alkermes Trading Down 0.3 %

NASDAQ ALKS opened at $35.89 on Monday. The company has a market cap of $5.81 billion, a PE ratio of 18.41, a PEG ratio of 1.83 and a beta of 0.49. The company has a current ratio of 3.45, a quick ratio of 3.03 and a debt-to-equity ratio of 0.22. Alkermes has a 12 month low of $22.90 and a 12 month high of $36.25. The stock has a 50 day moving average of $30.40 and a 200-day moving average of $28.81.

Insider Transactions at Alkermes

In other news, EVP Craig C. Hopkinson sold 144,419 shares of Alkermes stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $35.53, for a total transaction of $5,131,207.07. Following the completion of the sale, the executive vice president now owns 57,875 shares of the company’s stock, valued at approximately $2,056,298.75. This trade represents a 71.39 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Christian Todd Nichols sold 5,208 shares of Alkermes stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $29.15, for a total value of $151,813.20. Following the sale, the senior vice president now directly owns 60,703 shares of the company’s stock, valued at $1,769,492.45. This represents a 7.90 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 323,608 shares of company stock valued at $10,854,725. 4.89% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of ALKS. Sanctuary Advisors LLC bought a new position in shares of Alkermes in the second quarter worth $228,000. CWM LLC increased its position in shares of Alkermes by 83.4% in the third quarter. CWM LLC now owns 14,547 shares of the company’s stock worth $407,000 after purchasing an additional 6,615 shares during the period. Creative Planning increased its position in shares of Alkermes by 51.7% in the third quarter. Creative Planning now owns 50,629 shares of the company’s stock worth $1,417,000 after purchasing an additional 17,264 shares during the period. Vontobel Holding Ltd. increased its position in shares of Alkermes by 128.9% in the third quarter. Vontobel Holding Ltd. now owns 56,261 shares of the company’s stock worth $1,575,000 after purchasing an additional 31,687 shares during the period. Finally, V Square Quantitative Management LLC bought a new position in shares of Alkermes in the third quarter worth $29,000. Institutional investors own 95.21% of the company’s stock.

About Alkermes

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.